Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Lumacaftor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 24,833Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    European Commission Approves ORKAMBI for Cystic Fibrosis
    European Commission Approves ORKAMBI for Cystic Fibrosis

    05 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230620466996/en

    BUSINESSWIRE
    05 Jul 2023
    Share Share
    Vertex Announces Health Canada Market Authorization for ORKAMBI& in Children
    Vertex Announces Health Canada Market Authorization for ORKAMBI& in Children

    11 Apr 2023

    // BIOSPACE

    https://www.biospace.com/article/releases/vertex-announces-health-canada-market-authorization-for-orkambi-and-174-lumacaftor-ivacaftor-in-children-with-cystic-fibrosis-ages-1-to-and-lt-2-years/

    BIOSPACE
    11 Apr 2023
    Share Share
    Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq
    Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq

    05 Sep 2022

    // NASDAQ

    https://www.nasdaq.com/articles/vertex-vrtx-cf-drug-gets-fda-expanded-label-for-toddlers

    NASDAQ
    05 Sep 2022
    Share Share
    Vertex Announces U.S. FDA Approval for ORKAMBI in Children
    Vertex Announces U.S. FDA Approval for ORKAMBI in Children

    03 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220902005252/en

    BUSINESSWIRE
    03 Sep 2022
    Share Share
    ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis
    ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis

    23 Sep 2020

    // PRESS RELEASE

    https://icer-review.org/announcements/icer-issues-final-report-and-policy-recommendations-on-treatments-for-cystic-fibrosis/

    PRESS RELEASE
    23 Sep 2020
    Share Share
    Switzerland reaches reimbursement deal for Vertex CF drugs
    Switzerland reaches reimbursement deal for Vertex CF drugs

    22 Apr 2020

    // PRESS RELEASE

    https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-innovative-reimbursement-agreement-switzerland

    PRESS RELEASE
    22 Apr 2020
    Share Share